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ABSTRACT 
 
Venous leg ulcer (VLU) or stasis ulcer is a relatively common, chronic and recurring 
problem. Besides being costly to the health-care system, it significantly impairs the quality of 
life of the patients. Nearly 1% of adults and 3.6% of older patients are reported to suffer from 
this chronic condition. Chronic venous insufficiency is considered to be the predominant 
cause of VLU. The most recent theories associate the pathogenesis of venous ulcer with 
microcirculatory abnormalities and generation of an inflammatory response. The 
pharmacological treatment for VLU is based on the pathogenesis and often includes diosmin, 
pentoxifylline, diuretics as well as antibiotics and the non-pharmacological treatment like 
compression and skin grafting. VLU has a high rate of recurrence and requires self-care to 
avoid relapse. Treatment of VLU should always focus for complete treatment, and improve 
quality of life for patients along with minimum relapse. In recent years novel therapeutic 
approaches for venous ulcers have offered valuable tools for the management of patients with 
this disorder. 
 
Introduction  
Venous leg ulcers (VLU) or stasis ulcers are a chronic and 
recurring problem that is very taxing to the health-care system 
and significantly impair the quality of life of those who suffer 
from it. The incidence of chronic venous insufficiency is 
approximately 5.9% and the prevalence of venous ulcers is 
around 1% in the Western world [1]. The prevalence of VLU 
increases with age from 4% to 5% in elderly patient of ≥80 
years old [2,3]. Many studies suggest a higher prevalence of 
venous leg ulcers in women, but this disparity decreases with 
age [4]. 
VLUs account for 60-80% of lower leg ulcers [5]. Studies 
report that an average venous ulcer requires as much as 6 to 12 
months to heal completely and 70% of which could recur 
within 5 years of closure [6]. Chronic venous insufficiency is 
the most common cause of leg ulcers.  
 
Etiology 
 
Chronic venous insufficiency and related venous ulcers are 
predominantly caused by prolonged venous hypertension. This 
may occur due to one or more of the following reasons [7]. (1) 
Obstruction (venous outflow), for example secondary to deep 
vein thrombosis (DVT) or trauma (including previous lower 
limb fractures and surgery), pelvic mass, pregnancy, ascites, 
or obesity. (2) Venous reflux / Valvular incompetence, for 
example damage to valves via thrombophlebitis, as a 
consequence of ageing or congenital venous abnormalities. (3) 
Muscle pump failure, for example immobility related to 
ageing and co-morbid disease, paralysis or sedentary lifestyle. 
 
Pathophysiology 
 
Various theories have been put forward to explain the 
pathophysiology of venous ulcers, among them predominant 
theories are fibrin cuff and white blood cell trapping theory. 
According to the fibrin cuff theory, increased venous pressure 
causes leakage of macromolecules from plasma into 
perivascular space. This initiates the conversion of fibrinogen 
to fibrin and acts as a barrier to diffusion of oxygen and 
nutrients [6]. A recent hypothesis proposed that normal venous 
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circulation in the extremities is regulated by unidirectional 
valves that facilitate blood flow from capillary beds to the 
superficial system and finally to the deep venous system. 
When primary valvular dysfunction (the valves leading from 
the superficial to the deep venous system stop functioning 
properly), occurs it leads to localized ambulatory venous 
hypertension in the superficial veins [8,9]. 
Theory of white blood cell trapping suggests that the red blood 
cells and macromolecules which include fibrinogen and alpha-
2 macroglobulins, escape into dermis from circulation, due to 
venous hypertension. Since they cannot re-enter the 
circulation, they undergo degradation and the degraded 
products act as potent chemo-attractants. These inflammatory 
mediators attract leucocytes, and the resultant leukocyte’s 
migration and activation results in cytokine/growth factor 
release, soft tissue destruction, remodeling, dermal fibrosis 
and eventually ulceration [10]. Prolongation of this 
phenomenon induces transforming growth factor beta-1 (TGF 
beta-1), a cytokine released by macrophages and mast cells 
mediating dermal fibrosis in patient with severe ambulatory 
venous hypertension. TGF beta-1 binds to dermal fibroblast 
and regulates tissue remodeling by synthesis of collagen, 
regulation of metalloproteinase, differentiation of 
myofibroblast and extracellular matrix contraction [11]. 
Recent research has shown that fibroblasts from the edges of 
non-healing venous ulcers are unresponsive to TGF-beta-1, 
which may contribute to the overall failure in wound healing 
[12]. 
 
Clinical feature 
 
VLU’s are usually distributed in the calf, gaiter and foot 
region of the leg with distribution percentages of 5%, 87% and 
8% respectively (Figure 1) [13]. The size of the ulcer is 
usually large with irregular or ragged borders. Wound bed 
appears to be bright red with shallow depth (Table 1). The 
patient often gives history of pain, unpleasant odor, exudation, 
spontaneous bleeding and alteration of lifestyle. Clinical signs 
of venous disease include varicosities, hyper-pigmentation 
(due to hemosiderin staining), atrophie blanche, dermatitis, 
edema and lipodermatosclerosis (woody texture to the skin) 
[14]. Leg ulcers are often classified by their predominant 
etiology into venous and arterial leg ulcers. Venous and 
arterial leg ulcers are predominant followed by diabetic related 
ulcers. Comparison of clinical features of venous and arterial 
leg ulcers are summarized in table 1. 
 
Table 1: Clinical feature of venous and arterial leg ulcer 
Clinical feature Venous Arterial 
Location calf, goiter, foot region and medial aspect usually over tows, foot and ankle 
Depth Shallow deep 
Wound Edges irregular ragged bordered punched out 
Wound Bed bright red, fibrinous, loose slough or necrotic often covered with varying degree of slough 
and necrotic tissue 
Exudates copious, sometimes dripping, serous or bloody usually low 
Pain mild to severe, decreased with elevation or 
compression 
pain, even without infection 
Pulses readily palpable one edema is reduced  reduced or absent 
Associated features venous eczema, lipodermatosclerosis, 
atrophie blanche, hemosiderosis 
trophic changes; gangrene may be present 
 
Diagnosis  
Proper physical examinations as well as diagnostic 
investigation are crucial in deciding the right treatment option. 
Both limbs should be assessed for edema, temperature, and 
absence/loss of hair. Cold, clammy limb and loss of hair over 
the foot may indicate arterial insufficiency. Doppler 
measurement of the pressure at the ankle (dorsalis pedis or 
posterior tibial artery) in addition to the brachial artery is 
performed to determine Ankle Brachial Pressure Index 
(ABPI).  
ABPI = (Ankle Systolic Pressure / Brachial Systolic Pressure). 
Both the brachial and the ankle systolic pressures are obtained 
by using a portable Doppler. In a healthy vascular system, the 
ankle brachial pressure index is 0.9 to 1.2. An ABPI of 0.80-
0.9 indicates mild ischemia which may be the consequence of 
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an inflow disease; 0.50-0.79 indicates moderate ischemia; 
0.35-0.49 indicates moderately severe ischemia; 0.20
indicates severe ischemia and < 0.20 indicates critical 
ischemia [14]. 
Doppler ultrasonography is a method used to confirm venous 
reflux, but it cannot differentiate between superficial and deep 
venous insufficiency. Photoplethysmography (PPG), on other 
hand has an advantage of distinguishing between superficial 
and deep vein incompetence by measuring the extent of light 
absorption [15]. Duplex Doppler ultrasonography, a 
combination of ultrasonic scanning and pulsed Doppler flow 
examination, enables anatomical and functional assessment of 
the venous system but is not widely available [8].
Figure 1: Chronic ulcer on the medial malleolus
 
Treatment approaches 
 
Non pharmacological 
Non pharmacological approach includes appropriate dressing 
and graduated compression therapy. Current standard clinical 
approach to therapy includes lower limb compression along 
with leg elevation and debridement, which heals 40 to 60 
percent of venous leg ulcers. In a 2009 Cochrane review, 
evaluated a total of 39 randomized controlled trials and 
concluded that there was reasonable evidence to suggest limb 
compression healed venous ulcers more rapidly [21]. 
Debridement is also an important measure in
VLU [22]. Debridement of necrotic debris should be done as it 
encourages the growth of granulation tissue. However, the 
mainstay treatment for venous stasis ulcers is compression. 
Compression can be provided by dressings
multilayered bandaging, graduated compression stockings, or 
Velcro-strap devices. Compression materials used may be 
elastic or inelastic, like bandage wraps, Unna’s boot, elastic 
stockings and mechanical devices. Sustained graduated 
compression overcomes the effects of venous hypertension by 
reducing venous stasis and preventing tissue edema
European standard compression hosieries propose
classes of compression at the ankle: light compression (18.4
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The ulcer should be swabbed for microbiological testing, as 
more than 80% of leg ulcers may be colonized with bacteria 
[16,17,18]. The most common micro
wound are Pseudomonas aeroginosa, Staphylococcus aureus 
and Hemolytic streptococci, which can slow the ulcer healing 
process [19]. Musculoskeletal examination like goniometry 
(extent of joint movement) is sometimes warranted to assess 
loss of mobility at the ankle joint, loss of calf muscle pump 
function and loss of joint mobility of 
[20]. Complete blood count and random blood sugar should 
also be monitored before starting the treatment regimen.
 
 
 the treatment of 
: single or 
 [23]. 
s four 
–
21.1 mm Hg/2.5–2.8 kPa); medium (25.2
4.3 kPa); strong (36.5–46.6 mm Hg/4.9
strong (>59 mm Hg/>7.9 kPa). Light compression hosiery is 
indicated for treating mild varicose veins; medium 
compression for pronounced varicosity with edema and strong 
compression for late complications of constitutional or post
thrombotic venous insufficiency, atrophie blanche, 
dermatosclerosis [24]. However the most effective level of 
compression to overcome venous hypertension has been 
determined to be around 40 mm Hg at the ankle
recent Cochrane review provides the most complete overview 
on randomized controlled compression
ulcers and concluded that compression clearly increases the 
rate of healing as compared to no compression [25].
Treatment by multilayer e
effective form for the treatment of venous ulcer. The pressure 
sustained in this type of compression is between 40 and 45 
mmHg at the ankle and 17 mmHg below the knee.
multilayer compression materials have first lay
fabric applied as spiral, which absorbs exudates and 
redistributes pressure around the ankle. The second layer is a 
compression elastic bandage, and the top layer is an adhesive 
bandage that adequately sustains all layers [26]. This 
compression can last in the place for seven days with 
32 
-organisms infecting the 
the toes due to VLU 
 
–32.3 mm Hg/3.3–
–6.2 kPa); and very 
-
 [21]. The 
-trials in venous leg 
  
lastic compression is presently an 
 These 
er of woolen 
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sustained pressure, trauma protection, for wounds with 
exudates. The multilayer system is more effective than the 
traditional ones [27]. High compression is more effective than 
low compression, but the differences in effectiveness of the 
many types of high compression are not yet clear [28]. Choice 
of dressings may change during the course of therapy 
concomitant with the changing nature of the wound base and 
exudate. 
The effect of surgery and compression on healing and 
recurrence (ESCHAR) trial randomized 500 limbs to high 
ligation and stripping of the saphenous veins (saphenectomy) 
in addition to compression versus compression alone [29,30]. 
Initial results of ulcer healing were similar in both the groups 
(93% and 89%, respectively) but ulcer recurrence at 4 years 
(24% vs. 52%) was significantly better in the saphenectomy 
group. The study suggested that the correction of saphenous 
reflux prevented recurrence. In a recent study, considering 
compression as a form of medical saphenectomy, it was 
suggested that compression stockings mechanically compress 
the saphenous and deep veins (with higher pressures), thereby 
abolishing reflux [31].  
Ideally, compression should be accompanied by complete bed 
rest and leg elevation to relieve edema; however, this is not 
always practical [15]. Leg elevation helps in reducing edema 
and enhances flow in the microcirculation, reducing trapping, 
sequestration, and activation of white cells [21]. 
If conservative treatment by leg compression is unsuccessful, 
surgical intervention like skin grafting is required [32]. 
Grafting may be pinch graft which is advisable in patients 
with multiple medical problems, and can be performed on an 
outpatient basis and in primary care facilities [33]. Split 
thickness skin graft is used for large ulcers. These grafts need 
a large donor site as these may contract after harvesting and 
can be slow to heal, causing a lot of pain. Major disadvantage 
of large skin graft is treatment failure because of the build-up 
of exudates underneath the graft. This failure is best avoided 
by the use of a meshed graft [34]. Other adjunct treatment for 
venous ulcers includes electrical stimulation, negative pressure 
therapy, hyperbaric oxygen therapy, ultrasound, and low-
intensity laser therapy. However, the effectiveness of this 
adjunct treatment in amelioration of VLU is uncertain [35]. 
 
Pharmacological 
 
Antibiotics, diuretics pentoxifylline, aspirin and diosmin, are 
among the drugs, used in the treatment of VLU (Table 2). 
Antibiotics have little effect on ulcer healing and are needed if 
there is a clinical infection with surrounding periulcer 
erythema, swelling, cellulitis, purulence, tenderness and pain, 
and sometimes fever and malaise. In cases where infection 
results in septicemia, intravenous therapy of antibiotic is 
necessary [36]. Ulcers of less than 1 month duration usually 
are colonized by Gram-positive organisms (Staphylococcus 
aureus, and Group-A streptococcus). Cephalexin is an ideal 
choice of antibiotic, although cloxacillin is often used as well 
but does not adequately cover streptococcus species. Gram-
negative and anaerobic organisms may co-exist in ulcers of 
longer duration, and a broad spectrum of antibacterial 
coverage should be considered. 
Diuretics are among the most commonly used drugs in the 
treatment of edema associated with venous ulceration. 
Diuretics may help mobilize fluid in conjunction with 
aggressive compression therapy, but they are ineffective if 
given alone for edema control [37]. 
Pentoxifylline is a competitive nonselective phosphodiesterase 
inhibitor which raises intracellular cAMP, activates PKA, 
inhibits TNF and leukotrienes synthesis [38,39], and reduces 
inflammation. In a placebo controlled, double blind, 
randomized study out of 80 patients; 88% healed by 12 
months on pentoxifylline compared to 44% on placebo [40]. 
Aspirin has also been evaluated for the treatment of VLU in a 
small randomized clinical trial. In the study aspirin was 
compared with placebo and was found that 38% of ulcers 
healed with aspirin in comparison to 0% by placebo. However 
the validity of the study has been challenged by the weak 
methodology of the conducted trial [41]. 
Phlebotonic, which are flavonoid are either derived from plant 
source or prepared synthetically, like diosmin (derived from 
the flavonoid, hesperidins, found in citrus rinds) have been 
evaluated for their healing effect on VLU. The mechanism of 
action is not well established yet, but they seem to act on 
microcirculation, improve venous tonus, and decrease 
capillary hyper permeability [42]. Diosmin acts by reducing 
pain sensation, swelling, tension, and heaviness in the legs 
which are associated with chronic venous disease [43]. In a 
crossover study of the topical polymeric starch iodophore, 
(cadexomer iodine), patient’s condition improved with the 
treatment. Ulcers treated with cadexomer iodine showed 
trends toward less pain, exudation, pus, and debris, and a more 
rapid development of granulation tissue [44]. One multicentric 
RCT (Randomized Controlled Trial) compared mesoglycan 
(30 mg administered as daily intramuscular injection for three 
weeks followed by 100 mg orally daily) with placebo in 183 
patients with venous ulcer receiving compression therapy. The 
primary end point was time to healing of the target ulcer. At 
24 weeks the relative risk of healing was 1.48 (95% CI 1.05 to 
2.09) in favour of mesoglycan. Compared with other studies, 
the ulcers were of relatively short duration and the healing rate 
high. There were also differences at baseline between the 
groups and the use of compression bandaging was not 
standardized [45]. There is insufficient evidence to base a 
recommendation for mesoglycan in chronic VLU.  
Herbal therapy is also becoming increasingly popular among 
patients and physicians for treating VLU. An open, 
randomized controlled trial established the efficacy of new 
DermpalantG (contains dry water extract of Allii bulbus, dry 
ethanol extract of Hyperici herba and oily extract of 
Calendulae flos) herbal therapy in patients with non-infected 
venous leg ulcerations. The result of the study showed an 
accelerated process of epithelization and healing of certain 
venous ulcers without any observed adverse effects during the 
study and with good skin tolerance [14]. Herbal-based 
ointment Herbadermal® in a prospective non-randomized 
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pilot study showed 99.1% epithelization of ulcer after 7 weeks 
of treatment [31]. 
Several other advances are also under study and are offering 
promising results in the treatment of venous ulcers. Topical 
application of various growth factors [e.g., platelet-derived 
growth factor (PDGF), combination of platelet-derived 
wound-healing factors (PDWHF)], have been shown to 
accelerate healing of chronic non-healing ulcers [46,47,48]. 
 
 
Table 2: Treatment options for VLU 
 
Non Pharmacological compression, debridement 
skin grafting 
Pharmacological analgesics, antibiotics, diuretics, topical antimicrobials, local anesthetic, 
topical corticosteroids, pentoxifylline, phlebotonics 
growth factors (PDGF, PDWHF) 
Patient’s education and self-
care 
follow up care, leg elevation, smoking cessation 
 
Patients’ education and self-care 
 
Patient compliance and education is essential for the 
successful treatment of VLUs. Despite healing of a venous 
ulcer; each patient should receive sufficient follow-up care. 
The patient should be instructed about proper skin care and the 
importance of leg elevation and also to avoid prolonged 
standing. Appropriate rest is important for ulcer healing, since 
it decreases the effects of venous hypertension. During rest, 
the limb should be raised above the level of the heart, for at 
least 30 minutes, three or four times a day [49]. Short walks, 
three or four times a day, should be encouraged. Besides, 
patients should be encouraged to maintain their weight in a 
range considered normal, and to cease smoking [50]. Besides 
this, an evident educational program should be encouraged for 
primary care providers about their role in guiding the patient 
about the necessity for achieving an accurate diagnosis. 
 
 
Clinical studies 
 
Several clinical trials are currently underway to reveal new 
potential treatments and directions of the management of 
VLU’s. An open label, phase I trial of Protein Kinase C 
(cPKC) based formulation (HO/03/03) has shown promising 
results in advancing the healing rate of venous ulcer. A human 
amniotic membrane allograft (EpiFix), in an open randomized 
controlled trial has shown to be effective in healing wounds. 
Amniotic membrane is rich in growth factors which are 
essential elements in wound healing by inhibiting 
inflammation and infection and also by promoting 
proliferation and differentiation of keratinocytes [51,52]. 
A phase II study to investigate the efficacy, safety and 
tolerability of topical treatment with Nexagon is presently 
recruiting subjects. The preclinical evidence with Nexagon as 
a wound healing promoting agent was promising. Nexagon 
acts by inhibiting a protein named Connexin 43 found in the 
gap junction of epidermal cells. Evidence is provided by a 
study which suggested the up-regulation of Connexin 43 in 
ulcer wound in comparison to intact skin [53]. By down-
regulation of this protein in the ulcer site, the extent of 
migration of fibroblasts increases, thereby potentiating wound 
healing. A phase I clinical study of topical Fibroblast Growth 
Factor 1 for chronic ulcers however failed to elucidate the 
efficacy of the intervention in humans, but a certain wound 
closure action was reported in one of a preclinical study [54]. 
Venous ulcer fibroblasts demonstrate a lack of viable TGF-
receptor complexes, which may contribute to the chronicity of 
these wounds [21]. An elaborate study is needed to elucidate 
the wound healing potential of fibroblast growth factor 1. 
CureXcell, a product containing activated allogenic white 
blood cells (monocytes, macrophages, neutrophils, and 
lymphocytes from healthy donors) recently proved to be 
effective in treating ulcer which is difficult to heal. This study 
was a prospective, cohort trial that showed monocyte and 
macrophage activation results in enhanced phagocytosis and 
secretion of cytokines that promote healing [55]. 
 
Discussion 
 
The effective amelioration of the symptoms of VLU using 
pharmacotherapy and therefore avoiding the adverse events of 
surgery is an attractive and desirable goal. The lack of 
universally accepted and effective pharmacotherapy for 
venous disease highlights the multifactorial nature of the 
symptoms suffered by these patients. Factors like obesity, calf 
muscle pump function, co-morbidity (particularly cardiac 
disease) and other medication may all contribute to the 
symptoms thought to originate from venous incompetence. 
Clearly a multidisciplinary approach must be considered for 
their clinical management.  
Current research focuses on the role of superficial venous 
surgery and the use of cultured skin allografts. Optimization in 
level of compression for healing should be explored. Variety 
of cell derived soluble factors, proteolytic enzymes (proteases) 
and cytokines (growth, regulatory, and chemotactic factors); 
are thought to direct wound healing processes and are current 
targets for specific treatment [56]. Leg ulcers may reoccur 
with the same frequency of ulceration. Recurrence rates of 
venous ulcers after treatment are reported to be high 
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[57](Barranco 1974). Once the leg ulcer is healed, careful skin 
care, continuous vigilance, and strict use of compression 
hosiery must be emphasized. Ultimately, the treatment focus 
should move from treating active ulcers to prevention; which 
would undoubtedly be cheaper than their cure and would also 
improve quality of life for patients with VLU. 
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